Translating scientific knowledge into innovative solutions is key for societal progress and to bring our vision “Health for All, Hunger for None” to life. No one can leverage the full potential of these solutions alone – partnerships play a key role. That’s why we are working with both scientists and scientific institutions around the world to find new and sustainable solutions in health and agriculture.
Bayer Science Collaboration Explorer
Strengthening transparency in science collaborations
While collaborations are essential, partnerships between the public and private sector are seen by some with skepticism and a plea for more transparency has been made. With our new Bayer Science Collaboration Explorer, we want to address this concern and have started publishing information related to our scientific collaborations with external partners.
Explore our scientific collaborations
With the publicly accessible Bayer Science Collaboration Explorer, we invite you to discover our scientific collaborations using the database below where we disclose information on newly established contracts with universities, public research institutions, and individuals. The Explorer currently includes information about 300+ collaborations and will grow over time. In spring 2022, the Explorer was successfully audited by Deloitte (view audit report). The Explorer was initially rolled-out in Germany in September 2021. Since December 2022, the Explorer discloses contract-based research collaborations also in the United States, with the ambition to include additional countries in the future. Have a look yourself!
The Bayer Science Collaboration Explorer started with contract-based research collaborations in Germany in September 2021 and has extended its scope to the United States in December 2022. The disclosed partner types are universities, public research institutions, and individuals. The scope of the Bayer Science Collaboration Explorer will be extended stepwise.
Please find here a detailed definition of the in-scope partner types:
Universities: Institutions of higher learning providing facilities for teaching/research and authorized to grant academic degrees (including Medical Schools & University Hospitals)
Public Research Institutions: Non-university and non-enterprise research-focused organizations with a considerable part of public funding
Individuals: Science experts except of Health Care Professionals – in accordance with data privacy laws
Commercial businesses and Healthcare Professionals (HCPs) are currently excluded; however, all collaborations with HCPs are covered by Bayer’s “Transfer of Value” initiative and therefore not duplicated here.
Balancing the transparency requirements of the public with confidentiality needs of Bayer and our partners, the following details are disclosed for each collaboration listed above:
ID: External reference number assigned to every disclosed collaboration
Division: Name of partnering Bayer division (Pharmaceuticals, Crop Science, Consumer Health or Enabling Functions)
Subject of Collaboration: Meta category that best represents the scientific area of the collaboration
Collaboration Type: Meta category that best represents the type of collaboration (Advisory Board Agreement, Consultancy Agreement, R&D Agreement, Speaker Agreement, Sponsorship Agreement, Other Agreement)
Contract Partner(s): Name of partnering legal entity or individual (in case a partner does not consent to the disclosure, the partner's name gets anonymized (“undisclosed”) – in accordance with the law)
Country of Partner(s): Partner’s country of incorporation / residence
Country of Bayer Legal Entity: Bayer legal entity’s country of incorporation
Funding Committed: Financial range of total funding committed by Bayer over the entire contract duration – might get adjusted retroactively based in actuals or proactively in case of contract amendments (ranges: 0 Euro; 1 - 10.000 Euro; 10.001 - 100.000 Euro; 100.001 - 500.000 Euro; 500.001 - 1.000.000 Euro; 1.000.001 - 5.000.000 Euro; 5.000.001 - 10.000.000 Euro; 10.000.001 - 25.000.000 Euro; 25.000.001 Euro +); for all financial ranges, additional non-monetary transfer of value may apply which are not listed here. These can include for example materials or know-how transfer.
Effective Date: Date as of which the collaboration becomes effective
Status: Indication whether collaboration is ongoing (active) or completed (inactive)
Transparency is a top priority for Bayer. We are committed to build up and strengthen trust by making information accessible from a whole range of areas.
Crop protection safety studies
The Crop Science division of Bayer grants the public access to safety-relevant studies that the regulatory authorities use to approve product registrations for crop protection products.
Bayer is fully committed to disclosing information about its planned and ongoing clinical trials in humans. We believe that increased transparency while maintaining patient privacy will ultimately encourage innovation and benefit patients.
Complementing our in-house expertise with the know-how of excellent partners beyond Bayer - from academia and industry to startups - is an integral part of driving innovation impact at Bayer.